What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Nature Clinical Practice Gastroenterology &Hepatology

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/NCPGASTHEP0336PMID 16327832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cited by this paper
• Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study

  2005cited by this paper
• Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.

  2005cited by this paper
• How effective are the usual treatments for ulcerative colitis?

  2004cited by this paper
• Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.

  2003cited by this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2002cited by this paper
• Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

  1994cited by this paper

• [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)].

  2015cites this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

  2012cites this paper
• Randomized controlled clinical trials in mild-moderate ulcerative colitis.

  2012cites this paper
• Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

  2012cites this paper
• European evidence-based Consensus on the management of ulcerative colitis: Current management.

  2008cites this paper
• Drug Insight: aminosalicylates for the treatment of IBD

  2007cites this paper